US Preclinical CRO Market

ID: MRFR/HS/47586-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
US Preclinical CRO Market Research Report: Size, Share, Trend Analysis By Service Type (Biologics Testing, Small Molecule Testing, Toxicology Testing, Pharmacology Testing), By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases), By Validation Type (In Vivo Studies, In Vitro Studies, Comparative Studies, Regulatory Studies) and By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035
US Preclinical CRO Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.62%
2024 Market Size$ 1,379.7 Million
2025 Market Size$ 1,457.24 Million
2035 Market Size$ 2,517.69 Million
Key Players
Charles River Laboratories
Covance
PRA Health Sciences
Eurofins Scientific
Medpace
Wuxi AppTec
Trends
  • Increased Outsourcing of Preclinical Services
  • Technological Advancements in Research
  • Regulatory Compliance and Data Integrity
Opportunities
  • Focus on Cost Efficiency
  • Rising Demand for Drug Development
  • Advancements in Personalized Medicine
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Service Type (USD Million)
      1. 4.1.1 Biologics Testing
      2. 4.1.2 Small Molecule Testing
      3. 4.1.3 Toxicology Testing
      4. 4.1.4 Pharmacology Testing
    2. 4.2 Chemicals and Materials, BY Therapeutic Area (USD Million)
      1. 4.2.1 Oncology
      2. 4.2.2 Neurology
      3. 4.2.3 Cardiology
      4. 4.2.4 Infectious Diseases
    3. 4.3 Chemicals and Materials, BY Validation Type (USD Million)
      1. 4.3.1 In Vivo Studies
      2. 4.3.2 In Vitro Studies
      3. 4.3.3 Comparative Studies
      4. 4.3.4 Regulatory Studies
    4. 4.4 Chemicals and Materials, BY End User (USD Million)
      1. 4.4.1 Pharmaceutical Companies
      2. 4.4.2 Biotechnology Companies
      3. 4.4.3 Academic Institutions
      4. 4.4.4 Research Organizations
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Charles River Laboratories (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Covance (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PRA Health Sciences (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eurofins Scientific (LU)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Medpace (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Wuxi AppTec (CN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Syneos Health (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 KCR (PL)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pharmaron (CN)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY SERVICE TYPE
    3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA
    4. 6.4 US MARKET ANALYSIS BY VALIDATION TYPE
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY VALIDATION TYPE, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY VALIDATION TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SERVICE TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
      3. 7.2.3 BY VALIDATION TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Preclinical CRO Market Segmentation

US Preclinical CRO Market By Service Type (USD Million, 2025-2035)

  • Biologics Testing
  • Small Molecule Testing
  • Toxicology Testing
  • Pharmacology Testing

US Preclinical CRO Market By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases

US Preclinical CRO Market By Validation Type (USD Million, 2025-2035)

  • In Vivo Studies
  • In Vitro Studies
  • Comparative Studies
  • Regulatory Studies

US Preclinical CRO Market By End User (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic Institutions
  • Research Organizations

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.